Predictive Factors of Non-Inflammatory Small Bowel Obstruction After Bowel Resection in Crohn's Patients.

Background: The aim of the study was to investigate the risk factors associated with the development of small bowel obstruction (SBO) in Crohn's disease (CD) after small bowel resection (SBR) that are not due to active/recurrent inflammation.
Methods: We conducted a retrospective cohort study of patients who had SBR for active or complicated CD. Abstracted data included demographics, phenotype, therapies for CD, endoscopic disease recurrence, and several surgical variables. The primary outcome was the development of non-inflammatory SBO (NI-SBO) within 5 years after SBR.
Results: A total of 335 patients were included. The cumulative rates of NI-SBO at 6 months, 1 year, and 5 years were 5 (1.5%), 8 (2.4%), and 29 (8.9%), respectively. Variables associated with the development of NI-SBO were active macroscopic or microscopic inflammation in the surgical margins (13 (56%) vs. 65 (27%), P = 0.004), open resection (vs. laparoscopic resection) (12 (41.4%) vs. 60 (19.5%), P = 0.0006) and a higher median number of previous resections (2 (interquartile range (IQR) 2 - 3) vs. 1 (IQR 1 - 2), P = 0.0002). Only 21% of patients who developed NI-SBO required surgical intervention.
Conclusions: The incidence of NI-SBO after SBR in CD is low and associated with inflammation at the margins of the resected bowel, previous bowel resections, and an open laparotomy approach. Most NI-SBOs resolve with medical management.
Competing Interests: M. Zulqarnain: no conflict; F. Jaber: no conflict, V. Jahagirdar: no conflict; S. Alsakarneh: no conflict; A. Stanton: no conflict; N. Patel: no conflict; J. Gomez: no conflict; P. Beniwal-Patel: no conflict; D. Stein: AbbVie: consulting, speaking and teaching; Allergan: speaking; Bristol Myers Squibb: speaking and teaching; Pfizer: speaking and teaching; Takeda: speaking and teaching; M. F. Otterson: no conflict; A. Yarur: consultant Takeda, Bristol Myers Squibb, Pfizer, Arena.
(Copyright 2024, Zulqarnain et al.)